Thalidomide for the treatment of multiple myeloma
スポンサーリンク
概要
著者
-
Hattori Yutaka
Division Of Hematology Department Of Medicine Keio University School Of Medicine
-
Iguchi Toyotaka
Division Of Hematology Department Of Medicine Keio University School Of Medicine
-
Iguchi Toyotaka
Division Of Hematology Department Of Internal Medicine Keio University School Of Medicine
関連論文
- Single-institute phase 2 study of thalidomide treatment for refractory or relapsed multiple myeloma : Prognostic factors and unique toxicity profile
- Thalidomide-Induced Severe Neutropenia during Treatment of Multiple Myeloma
- Recurrence of Autoimmune Disease after Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma
- Multilineage Involvement of Light Microscopic Myeloperoxidase-Negative Acute Leukemia
- Thalidomide for the Treatment of Refractory Multiple Myeloma : Association of Plasma Concentrations of Thalidomide and Angiogenic Growth Factors with Clinical Outcome
- Elevated Level of Plasma Basic Fibroblast Growth Factor in Multiple Myeloma Correlates with Increased Disease Activity
- Thalidomide for the treatment of multiple myeloma
- Prospective study of combination therapy with low-dose thalidomide plus prednisolone ameliorating cytopenia in primary myelofibrosis
- Bone Marrow Angiogenesis and Anti-Angiogenic Therapy in Multiple Myeloma
- Post-transplant consolidation therapy using thalidomide alone for the patients with multiple myeloma : a feasibility study in Japanese population